Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?

Pfizer's 6.8% dividend yield, while high, appears sustainable despite a 90% reported payout ratio, as its $12.4 billion free cash flow significantly covers $9.6 billion in dividends paid. The company demonstrated operational resilience with 10% year-over-year revenue growth to $14.7 billion in its latest quarter and EPS of $0.51 exceeding its $0.43 quarterly dividend, alongside ongoing cost-reduction efforts and strategic acquisitions like Seagen. Trading at a P/E of 13, the stock may present value, despite investor concerns leading to a 5% year-to-date decline.

Analysis

Pfizer's high dividend yield of 6.8% appears sustainable, despite a headline payout ratio of 90% that is skewed by significant non-cash charges such as asset impairments and restructuring expenses in a prior quarter. A more indicative measure of dividend safety is the company's free cash flow, which at $12.4 billion over the trailing twelve months provides ample coverage for the $9.6 billion paid in dividends. Operationally, the company is showing positive momentum, reporting 10% year-over-year revenue growth to $14.7 billion in its most recent quarter, while its diluted earnings per share of $0.51 exceeded the quarterly dividend of $0.43. This performance is supported by a dual strategy of aggressive cost reduction and growth through strategic acquisitions, highlighted by the $43 billion purchase of Seagen. Despite these strong fundamentals and a low price-to-earnings multiple of 13, the stock's 5% year-to-date decline suggests that broad investor sentiment remains cautious.

Key Decisions for Investors

• Investors focused on income should look beyond the high earnings-based payout ratio and prioritize the strong free cash flow coverage, which indicates the 6.8% dividend yield is secure.
• The combination of a 13 P/E multiple and 10% operational revenue growth presents a potential value opportunity, particularly for investors confident in the company's ability to integrate acquisitions and execute its cost-cutting program.
• It is prudent to monitor the progress of the company's restructuring efforts and stay aware of developments in healthcare reform, which represents a significant, albeit unpredictable, long-term sector-wide risk.